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Objectives: In China there is a lack of awareness of HRT as a treatment option to alle-
viate climacteric symptoms apart from herbal or traditional Chinese medicines (CM). 
This study aims to assess economic impact of reimbursing 17-ß-estradiol combined 
HRT from Chinese payer’s perspective. MethOds: An economic analysis based on 
Danish Osteoporosis Prevention Study (DOPS) efficacy data was conducted to model 
an assumptive cohort of 100,000 women in 2 comparisons, namely HRT based on 2mg 
17-ß-estradiol and 10 mg Dydrogesterone versus mixed-treatment cohort, (including 
41% no treatment after clinical consultations and 59% treated using CM), and a second 
comparison of HRT versus 100% CM (50,000 for each group). Long-term fracture, car-
diovascular (CV) events and drug procurement costs are evaluated as main outcomes. 
Cost data are obtained from Shanghai Patient Electronic Medical Records. Daily drug 
cost is ¥4.39 for HRT based on the only available 17-ß-estradiol included combina-
tion drug in China and ¥12 for alternative treatment based on the market research. 
5-year continuous treatments with 65% compliance and 10% patients’ copayment 
are reported as base-case scenario. Results: The per person costs to achieve frac-
ture free 5 year for HRT, CM-59%, and CM-100% cohorts was ¥831, ¥1,370, and ¥2,276, 
respectively. The cost per CV event free 5 year for HRT, CM-59%, and CM-100% cohorts 
was ¥814, ¥1,363, and ¥2,275, respectively. The cost savings achieved with HRT com-
pared to CM-59%, and CM-100% cohorts was ¥544 and ¥1453, respectively. Comparing 
the costs for 50,000 women using HRT with CM-59%, and CM-100%, a savings of ¥143 
million and ¥369 million, respectively was achieved. cOnclusiOns: Although the 
willingness for Chinese menopausal women to seek treatment is quite low, treating 
all those who have sought clinical consultations with HRT rather than maintaining 
use of CM may save healthcare expenditure.
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Objectives: Bemfola, biosimilar follitropin alfa, has been launched in the 
Italian Market as a treatment for infertility. The aim of this project is to perform 
a cost-effectiveness evaluation comparing Bemfola to Gonal-f in an Italian con-
test. MethOds: Starting from “A multi-centre phase 3 study comparing efficacy 
and safety of Bemfola® versus Gonal-f in women undergoing ovarian stimulation 
for IVF” by Rettenbacher et al., a cost-effectiveness model was developed to compare 
costs and efficacies of the two comparators (Bemfola and Gonal-f) in an Italian 
contest. Clinical data on number of subjects, total dose of gonadotropins, pregnan-
cies and liveborn children, OHSS for both first and second cycle of the study by 
Rettenbacher et al. were used to feed the model. Costs related to drugs, DRG for ART, 
specialistic visits and examinations were retrieved from 2015 Italian tariffs. The 
perspective is the NHS one. Costs of Bemfola and Gonal-f arms were divided by the 
efficacies, i.e. live birth rate, in order to obtain an average cost per live birth and ICER 
was also calculated. Results: Gonal-f cost resulted to be € 3,550 whereas Bemfola 
cost resulted to be € 3,483. Efficacy, i.e. live birth rate, associated to Gonal-f was 0.52 
whereas it was 0.47 for Bemfola. The average cost per live birth was estimated to 
be € 6,787 for Gonal-f and € 7,449 for Bemfola. Furthermore, Gonal-f generated an 
ICER equal to € 1,210 compared to Bemfola, which is the additional cost required 
for Gonal-f to gain an additional live birth in comparison with Bemfola. Gonal-f, 
although it has a higher acquisition cost in comparison with Bemfola, provides a 
lower average cost per live birth and an ICER of € 1,210. cOnclusiOns: The results 
of this cost-effectiveness analysis indicate that Gonal-f is a cost-efficient treat-
ment strategy for the Italian health service compared to Bemfola in the treatment 
of infertility.
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Objectives: To estimate the cost-effectiveness of Nexplanon (etonogestrel 
implant) compared to other reimbursed contraceptive methods in 
France. MethOds: A 6 year cost effectiveness model was developed to assess the 
cost per unplanned pregnancy of different reimbursed methods (oral contracep-
tive pill (COC), hormonal intrauterine device (IUD), copper IUD and Nexplanon® 
among French women in the perspective of the French health care system. Efficacy 
inputs, including rate of pregnancies and discontinuation, as well as economic 
parameters of the model were estimated through an analysis of French claim 
database named EGB based on 2012 data (FACET study). Outcomes considered 
for contraceptive failure were birth, extra-uterine pregnancy, miscarriage and 
abortion. Costs of contraception and failures included device, drugs, exams and 
medical management (physician visits, procedures and hospitalizations) as 
reported in the database. A discount rate of 4% was applied to both efficacy and 
Objectives: At the most European countries the cost for assisted reproduc-
tive technology (ART) are compensated from state and insurance funds. At the 
first in Ukraine state funding of ART was launched on the Orders of MoH №579 
from 24.11.2004. However, most patients have to pay own out-of-pocket costs for 
ART. MethOds: We evaluated the general cost of short and long stimulation pro-
tocols for ART of new Order of MOH Ukraine №771 from 23.12.2008 “On Approval 
of Instruction on the use of assisted reproductive technologies”. Cost analysis for 
short and long protocols, based on the comparison of costs during 2014 and 2015 in 
Ukraine. Results: We used the prices from database Morion (Kiyv) on 01.04.2015 
and analysed the cost for short protocol. The stimulation of superovulation with 
Puregon was 18000 UAH (1Euro= 24.7 UAH) or with Elonva was 13 000 UAH. Also 
cost on other medicines were included. In average, a general cost per 1 cycle was 
16 600 UAH. Were analyzed the cost of ART long protocol. We included the cost 
with Diferelin depot that was 2800 UAH. The cost of stimulation of superovulation 
with Puregon was 18000 UAH. In average, a general cost per 1 cycle was 24 000 UAH. 
We compared the cost data on ART during 2014-2015. The average salary was 3998 
UAH on 01.04.2015 in Ukraine. cOnclusiOns: Comparing data 2014 and 2015 were 
founded, that the cost of short protocol increased by 27% and by 41% the long one. 
It was established that the cost of ART are high. Revealed that the cost of ART is 4-6 
times higher than the average salary, therefore the availability of ART for families 
is low. It is necessary to determine the budget financing for ART to improve access 
to ART in Ukraine.
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Objectives: Preeclampsia has a high prevalence rate and it’s the second leading 
cause of maternal mortality. In developing countries a preeclampsia is the cause of 
50 000 deaths each year. An effective method of preeclampsia prevention in accord-
ance with WHO guidelines, is a prescription of antiplatelet drugs. MethOds: 
Analysis of consumed drugs for pregnant women, according to the real practice 
of the district hospital in Lviv region during 2014. Systematization of evidence 
data about the effectiveness of prevention and treatment of preeclampsia, which 
were published in the databases Cochrane, Pubmed, ClinicalTrials.gov Results: 
The analysis of 112 medical records pregnant inpatients, who were hospitalized 
in September-December 2014, were conducted. For 42 (38%) patients were diag-
nosed the preeclampsia. For treatment intended antiplatelet drugs for 17 patients 
that only 40% were taking effective treatment. Other patients received various 
vitamins and antioxidants that have not confirmed evidence-effectiveness. The 
analysis of databases showed that recent RCTs (2013) indicate that antiplatelet 
therapy reduced the risk of pre-eclampsia by 21%. In randomize studies found 
that reduced level of neonatal mortality on 16% and the frequency of children 
born with low birth weight on 8%. In Ukraine, were registered 23 trade names of 
aspirin, including 11 from ukranian manufacturers. We calculated the costs of 
prevention during 5 months per patient (1 USD= 22,3 UAH on 30.05.2015). Costs 
ranged from 3,10 USD to 15,5 USD. The best choice of affordable was aspirin in 75 
mg with total costs 4,67 USD. cOnclusiOns: We established that treatment with 
low doses of aspirin 75 mg / day in early pregnancy for women with high risk of 
preeclampsia is an effective prevention of preeclampsia. In Ukraine the patients 
have to pay out of pocket , than the necessary information support of doctors in 
hospitals on effective and affordable prevention of preeclampsia by antiplatelet 
schemes.
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Objectives: National Drug Information Center (NDIC) has started providing ser-
vices since January 2013; and answering public and professional inquires through 
MOH-Hotline Calling Services (937) since December 2013. The objective of this study 
was to estimate cost-efficiency of NDIC in Saudi Arabia using American model 
of drug information inquires cost avoidance. MethOds: Simulation including 
all 12-month 2014 of receiving adults and pediatrics drug information inquiries 
through MOH-Hotline Calling Services (937). Ten on-call clinical Pharmacists and 
expert trained pharmacists were receiving calls from public and professional asking 
about drug information, through manual documentation system of drug informa-
tion inquiries by data collecting form. Using international Study Model (Kinky et 
al, Ann Pharmacother 1999), the cost considered were the expected results of drug 
related problems sequel of drug information inquires if not existing drug infor-
mation services and were not answered; starting from Physician visit, additional 
treatment, hospital admission to death stage. Results: The total number answered 
calls were 976 calls, with 264 (27%) answered calls were documented; the aver-
age costs avoidance per each answered call was (415.78 USD), and total cost was 
(109,768 USD) with partial documentation, the estimated total cost with complete 
documentation was (405,801 USD) per year. The cost avoidance of answering public 
inquiries was (80,806.5 USD) and Professional inquires was (28,961.5 USD). The high-
est cost avoidance based on type of inquires was dose standardization (34,195 USD), 
drug administration (21,324 USD) followed by drugs in pregnancy (15,826 USD) and 
Adverse a Drug reaction (12,793 USD). The highest cost avoidance was Antibacterial 
expected related problem (33,454.5 USD) cOnclusiOns: In this National Drug 
Information Center cost-efficiency simulation for Saudi Arabia, hotline line calling 
services - Drug Information associated with cost savings per each receiving call. 
expanding the answering drug information services with electronic documentation, 
